This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEA6606G_M.jpg
Biomarin Pharma sees FY 2023 EPS of $1.80-$2.05 versus the analyst consensus of $1.61.
Biomarin Pharma sees FY 2023 revenue of $2.38B-$2.50B versus the analyst consensus of $2.58B.
Biomarin Pharma’s stock price closed at $93.00. It is down -20.70% in the last 3 months and up 15.80% in the last 12 months.
Biomarin Pharma saw 0 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Biomarin Pharma’s stock price’s past reactions to earnings here.
According to InvestingPro, Biomarin Pharma’s Financial Health score is “good performance“.
Check out Biomarin Pharma’s recent earnings performance, and Biomarin Pharma’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
